Are Temporal Differences in GDNF and NOS Isoform Induction Contributors to Neurodegeneration? A Fluorescence Microscopy-Based Study.

CONCLUSION: Our findings suggest that the protective abilities of GDNF to combat neural destruction are not available rapidly enough, and do not remain at sufficiently high levels long enough to assert its protective effects. (250). PMID: 27651844 [PubMed]
Source: The Open Neurology Journal - Category: Neurology Tags: Open Neurol J Source Type: research

Related Links:

Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
We examined whether Rhy promotes this regulation in bone marrow human mesenchymal stromal cells (BM-hMSCs). Results revealed (i) Rhy modulated biological activity by regulating the mitochondria, N-methyl-D-aspartate receptor subunit, and levels of FGFβ (basic fibroblast growth factor), BDNF (brain-derived neurotrophic factor), OXTR (oxytocin receptor) and ATP (Adenosine triphosphate); (ii) Rhy altered expression level of BM-MSC proliferation/differentiation-related transcription genes; and (iii) interestingly, Rhy amplified the glycolytic flow ratio and lactate dehydrogenase activity while reducing pyruvate dehydrogen...
Source: Cytotherapy - Category: Cytology Source Type: research
Parkinson's disease (PD) is the second most common neurodegenerative illness, affecting approximately 1.5 million Americans. Described by many PD patients and families as an insidious “thief,” it progressively diminishes quality-of-life, self-image, and the ability to be independent. The late stage of PD can be protracted with inexorable changes in physical and mental health, altered relationships, and social isolation, all leading to increased suffering. There is significant evidence that many of the greatest needs of PD patients and their caregivers (e.g.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
ConclusionThis study showed that PD is a costly neurodegenerative disease that may pose a significant economic burden on patients, health care system and society.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Non-motor symptoms such as cognitive and gastrointestinal (GI) symptoms are common in Parkinson's disease (PD). In PD, GI-symptoms often present prior to motor symptoms. It is hypothesized that GI-symptoms reflect disruptions of the microbiome-gut-brain axis, which leads to altered immune functioning, chronic neuroinflammation, and subsequent neurodegeneration. Initial evidence links gut-dysbiosis to PD pathology and motor symptom severity. The present study examines the longitudinal relationship between severity of GI-symptoms and cognitive impairment in newly diagnosed PD patients.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research
ConclusionHemoglobin levels in PD seem to be closely related to noradrenergic nervous activity and nigrostriatal dopaminergic degeneration. In contrast to expectations, decreased hemoglobin levels were associated with increased whole-body sympathetic nervous activity in PD.
Source: Clinical Autonomic Research - Category: Research Source Type: research
In this study, we used chemoinformatics tools and molecular docking simulations to analyze molecules that have been experimentally tested and bound to α-synuclein, causing neuroprotective or neurotoxic activity, and whose results have been used to select potential natural neuroprotective molecules. We identified 6 potential natural neuroprotective molecules that are similar in their chemical structure to neuroprotective molecules and have a high number of hydrogen bonds with α-synuclein. We expect that these molecules may lead to the design or discovery of new effective treatments for Parkinson's disease.Graphical abstract
Source: Journal of Molecular Graphics and Modelling - Category: Molecular Biology Source Type: research
Abbott Laboratories is adding some extra firepower to its neuromodulation offerings. The company said last week that its Infinity Deep Brain Stimulation [DBS] device received a nod from FDA to treat Parkinson’s disease symptoms. The newly approved indication specifically calls for the Infinity DBS to target an area of the brain called the globus pallidus (GPi). Abbott said the GPi plays an integral role in the motor function and can be targeted with DBS to improve Parkinson’s disease symptoms not adequately controlled by medication. Abbott said with this approval, the Infinity DBS is now...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Business Source Type: news
Abbott has announced that the FDA has given the company the first ever approval for a device to treat Parkinson’s by delivering deep brain stimulation (DBS) to the internal globus pallidus (GPi), an area associated with motor function. The Infi...
Source: Medgadget - Category: Medical Devices Authors: Tags: Neurology Neurosurgery Source Type: blogs
Abbott's Infinity™ DBS is the first FDA approved directional Deep Brain Stimulation (DBS) system to allow targeting of a specific area of the brain that is critical to motor functions Approximately 60,000 Americans are diagnosed with Parkinson's disease... Devices, Neurology, FDA Abbott, Infinity, Deep Brain Stimulation, Parkinson's Disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Neurology | Parkinson's Disease | Study